The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue
- 15 February 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 194 (4) , 1737-1747
Abstract
The inducible costimulator (ICOS) plays a key role in the development of Th17 cells, but its role in the development and antitumor activity of IL-17–producing CD8+ T cells (Tc17) remains unknown. We found that ICOS costimulation was important for the functional maintenance, but not differentiation, of Tc17 cells in vitro. Blocking the ICOS pathway using an antagonist mAb or by using recipient mice genetically deficient in the ICOS ligand reduced the antitumor activity of adoptively transferred Tc17 cells. Conversely, activating Tc17 cells with an ICOS agonist in vitro enhanced their capacity to eradicate melanoma and induce autoimmune vitiligo when infused into mice. However, ICOS stimulation did not augment the antitumor activity of IL-2 expanded T cells. Additional investigation revealed that ICOS stimulation not only increased IL-2Rα, CXCR3, and IL-23R expression on Tc17 cells, but also dampened their expression of suppressive molecule CD39. Although Tc17 cells activated with an ICOS agonist cosecreted heightened IL-17A, IL-9, and IFN-γ, their therapeutic effectiveness was critically dependent on IFN-γ production. Depletion of IL-17A and IL-9 had little impact on antitumor Tc17 cells activated with an ICOS agonist. Collectively, our work reveals that the ICOS pathway potentiates the antitumor activity of adoptively transferred Tc17 cells. This work has major implications for the design of vaccine, Ab and cell-based therapies for autoimmunity, infectious disease, and cancer.Keywords
This publication has 62 references indexed in Scilit:
- Th17 Cells in Cancer: The Ultimate Identity CrisisFrontiers in Immunology, 2014
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 TherapyCancer Immunology Research, 2013
- Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct MechanismsThe Journal of Immunology, 2013
- Robust tumor immunity to melanoma mediated by interleukin-9–producing T cellsNature Medicine, 2012
- Human T H 17 Cells Are Long-Lived Effector Memory CellsScience Translational Medicine, 2011
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical TrialClinical Cancer Research, 2010
- T-Cell Engineering for Cancer ImmunotherapyThe Cancer Journal, 2009
- Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cellsNature Immunology, 2007
- Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cellsJournal of Experimental Medicine, 2005